Investigation of potent anticarcinogenic activity of 1, 3-diarylpyrazole acrylamide derivatives in vitro

dc.contributor.authorDemiroğlu-Zergeroğlu, Asuman
dc.contributor.authorAyvali, Nurettin
dc.contributor.authorTurhal, Gulseren
dc.contributor.authorCeylan, Hurmuz
dc.contributor.authorBaytas, Sultan Nacak
dc.date.accessioned2025-10-29T11:13:35Z
dc.date.issued2018
dc.departmentFakülteler, Temel Bilimler Fakültesi, Moleküler Biyoloji ve Genetik Bölümü
dc.description.abstractObjectives Pyrazole derivatives are pharmacologically powerful agents pointing at new horizons in the development of anticancer therapies. In this study, anticarcinogenic potential of a series of pyrazole-acrylamide derivatives has been investigated in mesothelial, malignant mesothelioma and lung cancer cell lines. Methods Key findings The effect of compounds on the viability of cells and the distribution of cell cycle were examined through MTS assay and PI staining, respectively. Apoptosis was evaluated via caspase-3 enzymatic assay and AO/EB staining. Proteins involved in proliferation, survival and apoptosis were analysed by immunoblotting. Twelve compounds of 21 (4a-4v) reduced the viability of cells but, only the subset of five (4f, 4i, 4j, 4k and 4v) induced the caspase-3 activity. Among five, only one compound (4k) significantly suppressed phosphorylation and expression of ERK1/2 and AKT proteins in 24 h. Exposing cancer cells to successive concentrations of 4k gave rise to dose- and time-dependent G2/M phase arrest and apoptosis. Conclusions 4k has revealed its potent antiproliferative activity by decreasing viability and inhibiting proliferation and survival signals of cancer cells. Moreover, 4k has exposed cytostatic and apoptotic effect especially, on cancer cells. Therefore, it may be necessary to examine the biological actions of 4k in vivo as well.
dc.description.sponsorshipInternal Grant of Gebze Technical University [BAP 2013-A-08] Funding Source: Medline
dc.description.sponsorshipScientific Research Grant by Gazi University [02/2009-21] Funding Source: Medline
dc.identifier.doi10.1111/jphp.13012
dc.identifier.endpage1629
dc.identifier.issn0022-3573
dc.identifier.issn2042-7158
dc.identifier.issue12
dc.identifier.orcid0000-0002-5826-1305
dc.identifier.orcid0000-0002-9929-6467
dc.identifier.orcid0000-0001-6272-7158
dc.identifier.pmid30198567
dc.identifier.scopus2-s2.0-85053041751
dc.identifier.scopusqualityQ2
dc.identifier.startpage1619
dc.identifier.urihttps://doi.org/10.1111/jphp.13012
dc.identifier.urihttps://hdl.handle.net/20.500.14854/6833
dc.identifier.volume70
dc.identifier.wosWOS:000449687300004
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Pharmacy and Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20251020
dc.subjectMalignant Mesothelioma
dc.subjectERK1-2
dc.subjectAKT
dc.subjectcell cycle
dc.subjectapoptosis
dc.titleInvestigation of potent anticarcinogenic activity of 1, 3-diarylpyrazole acrylamide derivatives in vitro
dc.typeArticle

Dosyalar